We’re pleased to provide the latest coverage from Edison Research on Kazia’s recent initial efficacy data from its phase II trial of GDC-0084 in glioblastoma.
The report states that the data is “very encouraging” and that it is “sufficient to give Kazia confidence that it can run a large, and potentially pivotal, study starting by mid-CY20.”
Edison also states that it assumes that this single pivotal trial might be adequate for FDA approval of GDC-0084 in 2024 “as patients resistant to the current standard therapy, temozolomide, have no other options available.”
Edison has a valuation on Kazia of A$137 million.
You can read the full research report, which includes a video interview with CEO, Dr James Garner, on GDC-0084 here
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.